12,372 trials
Infections, Streptococcal
Primary: Antibody Concentrations Against Vaccine Pneumococcal Serotypes — 1.24; 7.63; 4.52; 12.95 μg/mL
Malaria
Primary: Anti-Circumsporozoite (Anti-CS) Antibody Titers — 319.6; 241.4; 302.3; 285.8 Titers
Knee Osteoarthritis
Primary: Change in Pain According to VAS (0-100 mm) — -11.86; -20.57 units on a scale — p=<0.0307
PONV
Primary: Number of Participants With Complete Response — 330; 268 Participants — p=<0.001
Thyroid Neoplasm · Goiter
Primary: NRS Pain Scores for the First 12 Hours — 4.93; 4.12; 4.50; 3.69 points — p=0.008
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Activity Against Neisseria Meningitidis Serogroups A, C (rSBA-MenA, C) Using Rabbit Complement Antibodies — 116; 66; 192; 53…
HIV Infection
Primary: Number of Participants Who Quit Hazardous Drinking — 44; 39 Participants — p=0.36
Epilepsy · Monotherapy
Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum of 3.5 Years) — 181; 182 Participants
Anemia
Primary: Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia — 37; 15 Participants
Type 2 Diabetes
Primary: Absolute Change in the Endothelial Progenitor Cell (EPC) Number — 37; 36; 45; 32 EPC/10^6 cells — p=<0.05
Polycystic Ovary Syndrome
Primary: Number of Menses During the Six Month Study Period. — .42; .42; .75; .25 Number of menstrual cycles per month
Anemia
Primary: To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag. — 0.147; 0.063 g/dL
Inflammation of Mouth · Acute Mucous Inflammation
Primary: Wound Size (mm^2) Reduction — 11.26; 8.92 mm^2
Psoriatic Arthritis
Primary: Proportion of ACR 20 Responders at Day 169 — 39.4; 22.3 Percentage of participants — p=<0.001